In this episode of the EP Edge Newsletter Podcast, we analyze the pivotal clinical trials that established pulsed field ablation (PFA) as a major technological advancement in atrial fibrillation ablation. We examine the foundational FDA-approval studies, including the PULSED AF trial evaluating the Medtronic PulseSelect system and the ADVENT randomized trial comparing FARAPULSE pulsed field ablation with conventional radiofrequency and cryoballoon ablation. These trials demonstrated that pulsed field ablation achieves high rates of acute pulmonary vein isolation with freedom from atrial arrhythmia recurrence comparable to thermal ablation, while maintaining a favorable safety profile and procedural efficiency. Importantly, these studies defined modern clinical endpoints for catheter ablation success, including composite measures incorporating arrhythmia recurrence, antiarrhythmic drug use, cardioversion, and repeat ablation. PFA Part IIWe also explore next-generation pulsed field ablation platforms, including the Sphere-9 lattice-tip catheter, VARIPULSE system, and VOLT balloon-in-basket catheter, each designed to improve lesion durability, catheter stability, and procedural reproducibility. These studies demonstrate consistently high rates of pulmonary vein isolation, favorable safety outcomes, and evolving workflow advantages, including reduced fluoroscopy use and efficient lesion delivery. We then examine the latest randomized and investigational trials, including INSIGHT, which compared nanosecond pulsed field ablation with optimized ablation-index guided radiofrequency ablation, and the PULSAR IDE trial evaluating spherical array catheter design for durable pulmonary vein isolation. These trials highlight a critical reality in atrial fibrillation ablation: long-term success is determined not only by energy source, but by catheter design, tissue contact, lesion geometry, and pulmonary vein isolation durability. PFA Part IIFull references, detailed discussion, figures, and graphical summaries are available on the EP Edge Newsletter on LinkedIn, as well as the complete long-form article on Substack at epedge.substack.com. If you have questions, suggestions, or feedback, please contact epedgecast@gmail.com.
AI Summary coming soon
Sign up to get notified when the full AI-powered summary is ready.
Free forever for up to 3 podcasts. No credit card required.
EP Edge Newsletter Part III: Pulsed Field Ablation Complications — Hemolysis, Coronary Spasm, Silent Stroke, Phrenic Nerve Injury, and CIED Interaction
EP Edge Newsletter Part I: Pulsed Field Ablation (PFA) — Electroporation, Biophysics, Engineering, Tissue Selectivity, and Lesion Formation
Cannabis and the Heart: Atrial Fibrillation, Arrhythmias, Stroke, Myocardial Infarction and Sudden Cardiac Risk Explained
When Atrial Fibrillation Ablation Fails: Have We Reached the Limit or Just the Wrong Target?
Free AI-powered recaps of EP Edge and your other favorite podcasts, delivered to your inbox.
Free forever for up to 3 podcasts. No credit card required.